AS-601811

AS-601811
Clinical data
Other names	AS-601811; AS601811
Routes of; administration	Oral
Drug class	5α-Reductase inhibitor
ATC code	None;
Identifiers
	IUPAC name 4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one;
CAS Number	194979-95-8;
PubChem CID	10220187;
UNII	LIV8A6AE5F;
ChEMBL	ChEMBL118319;
Chemical and physical data
Formula	C15H17NO
Molar mass	227.307 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC2=C(C=C1)N3CCC(=O)C(=C3CC2)C;
	InChI InChI=1S/C15H17NO/c1-10-3-5-14-12(9-10)4-6-13-11(2)15(17)7-8-16(13)14/h3,5,9H,4,6-8H2,1-2H3; Key:SNEPAAKJPPNOQM-UHFFFAOYSA-N;

AS-601811 is a 5α-reductase inhibitor of type 1 of the enzyme which was under development for the treatment of acne, benign prostatic hyperplasia, hirsutism, male-pattern baldness, and prostate cancer but was never marketed.^[1]^[2] It is taken orally.^[1] The drug reached phase 1 clinical trials prior to the discontinuation of its development.^[1] It was being developed by Merck Serono.^[1]^[2]

References

1 2 3 4 5 "AS 601811". AdisInsight. 12 March 2008. Retrieved 23 October 2025.
1 2 Voegeli R, Zouboulis CC, Elsner P, Schreier T (17 May 2007). "5a-Reductase and Its Inhibitors". In Webster GF, Rawlings AV (eds.). Acne and Its Therapy. CRC Press. pp. 181–216. doi:10.3109/9781420018417-18. ISBN 978-0-429-16389-0. Retrieved 23 October 2025.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.

This dermatologic drug article is a stub. You can help Wikipedia by adding missing information.